Molecular Partners AG (MLLCF)
USD 4.22
(0.24%)
USD 4.22
(0.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.92 Million CHF | -19.08% |
| 2022 | 27.09 Million CHF | -58.56% |
| 2021 | 65.37 Million CHF | -18.61% |
| 2020 | 80.32 Million CHF | 58.13% |
| 2019 | 50.79 Million CHF | -19.95% |
| 2018 | 63.45 Million CHF | 129.12% |
| 2017 | 27.69 Million CHF | -42.67% |
| 2016 | 48.3 Million CHF | -28.55% |
| 2015 | 67.6 Million CHF | 48.44% |
| 2014 | 45.53 Million CHF | -26.31% |
| 2013 | 61.79 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 17.06 Million CHF | -22.18% |
| 2024 Q2 | 15.04 Million CHF | -11.79% |
| 2023 Q3 | 21.9 Million CHF | -10.63% |
| 2023 Q1 | 22.37 Million CHF | -17.43% |
| 2023 Q2 | 24.51 Million CHF | 9.59% |
| 2023 FY | 21.92 Million CHF | -19.08% |
| 2023 Q4 | 21.92 Million CHF | 0.06% |
| 2022 Q1 | 47.34 Million CHF | -27.58% |
| 2022 Q3 | 29.73 Million CHF | -11.04% |
| 2022 Q4 | 27.09 Million CHF | -8.87% |
| 2022 FY | 27.09 Million CHF | -58.56% |
| 2022 Q2 | 33.42 Million CHF | -29.41% |
| 2021 Q2 | 72.34 Million CHF | -7.57% |
| 2021 Q4 | 65.37 Million CHF | 25.88% |
| 2021 FY | 65.37 Million CHF | -18.61% |
| 2021 Q1 | 78.27 Million CHF | -2.55% |
| 2021 Q3 | 51.93 Million CHF | -28.21% |
| 2020 Q4 | 80.32 Million CHF | 0.0% |
| 2020 FY | 80.32 Million CHF | 58.13% |
| 2020 Q2 | 42.32 Million CHF | 0.0% |
| 2020 Q1 | - CHF | -100.0% |
| 2019 FY | 50.79 Million CHF | -19.95% |
| 2019 Q3 | 50.79 Million CHF | -10.6% |
| 2019 Q1 | 56.81 Million CHF | -10.46% |
| 2019 Q2 | 56.81 Million CHF | 0.0% |
| 2019 Q4 | 50.79 Million CHF | 0.0% |
| 2018 FY | 63.45 Million CHF | 129.12% |
| 2018 Q1 | 6.64 Million CHF | -75.99% |
| 2018 Q4 | 63.45 Million CHF | 72.12% |
| 2018 Q3 | 36.86 Million CHF | 232.24% |
| 2018 Q2 | 11.09 Million CHF | 66.91% |
| 2017 Q3 | 14.14 Million CHF | -66.93% |
| 2017 Q4 | 27.69 Million CHF | 95.84% |
| 2017 FY | 27.69 Million CHF | -42.67% |
| 2017 Q1 | - CHF | -100.0% |
| 2017 Q2 | 42.76 Million CHF | 0.0% |
| 2016 Q1 | - CHF | -100.0% |
| 2016 Q2 | 59.18 Million CHF | 0.0% |
| 2016 Q4 | 48.3 Million CHF | 0.0% |
| 2016 FY | 48.3 Million CHF | -28.55% |
| 2016 Q3 | - CHF | -100.0% |
| 2015 FY | 67.6 Million CHF | 48.44% |
| 2015 Q1 | - CHF | -100.0% |
| 2015 Q4 | 67.6 Million CHF | 0.0% |
| 2015 Q2 | 50.53 Million CHF | 0.0% |
| 2014 Q1 | - CHF | 0.0% |
| 2014 FY | 45.53 Million CHF | -26.31% |
| 2014 Q4 | 45.53 Million CHF | 0.0% |
| 2013 FY | 61.79 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ContraFect Corporation | 32.53 Million USD | 32.609% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 58.873% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -128.793% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -5100.347% |
| SQZ Biotechnologies Company | 50.03 Million USD | 56.188% |
| Intellipharmaceutics International Inc. | 12 Million USD | -82.558% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 69.749% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 62.851% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -469.218% |
| Marizyme, Inc. | 26.67 Million USD | 17.817% |
| Genus plc | 485 Million USD | 95.48% |
| Pharming Group N.V. | 244.07 Million USD | 91.018% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -990.626% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -771.23% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -476.921% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -472.754% |
| IMV Inc. | 37.93 Million USD | 42.206% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -86.132% |
| ONE Bio Corp. | 27.49 Million USD | 20.268% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 71.682% |
| Neon Bloom, Inc. | 1.22 Million USD | -1687.862% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -326.017% |
| Biomind Labs Inc. | 1.49 Million USD | -1362.887% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 81.534% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -19.125% |
| Skye Bioscience, Inc. | 14.07 Million USD | -55.789% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1428.949% |
| Mesoblast Limited | 188.44 Million USD | 88.366% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -15328.411% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -131.599% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -10800.674% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -281.547% |
| GB Sciences, Inc. | 5.41 Million USD | -304.666% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1355120.781% |
| Alpha Cognition Inc. | 7.16 Million USD | -205.983% |
| HST Global, Inc. | 593.59 Thousand USD | -3593.271% |
| CSL Limited | 18.62 Billion USD | 99.882% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 2.51 Million USD | -773.233% |
| Halberd Corporation | 728.71 Thousand USD | -2908.43% |
| Enzolytics Inc. | 365.26 Million USD | 93.998% |
| Resverlogix Corp. | 67.39 Million USD | 67.471% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2513.827% |
| argenx SE | 444.95 Million USD | 95.073% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1179.055% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 73.566% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -498.145% |
| Bioxytran, Inc. | 3.24 Million USD | -574.658% |
| Zenith Capital Corp. | 27.56 Thousand USD | -79420.476% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -487.07% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3120.021% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -708.477% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.347% |
| Kadimastem Ltd | 3.5 Million USD | -525.502% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -32655.607% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -142.452% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 56.384% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -275.225% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1006.491% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -1931.339% |
| EV Biologics, Inc. | 2.11 Million USD | -936.515% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -4617.677% |
| Q BioMed Inc. | 8.13 Million USD | -169.558% |
| LadRx Corporation | 2.2 Million USD | -896.261% |
| Cell Source, Inc. | 15.8 Million USD | -38.694% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -48949.132% |
| Regen BioPharma, Inc. | 5.45 Million USD | -301.696% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 70.738% |
| Itoco Inc. | 1.65 Million USD | -1226.134% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -968.599% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1641.036% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 11.408% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -262.424% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -84.179% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -448.933% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -9086.102% |
| NovAccess Global Inc. | 7.86 Million USD | -178.893% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -52348.623% |
| BioStem Technologies, Inc. | 15.9 Million USD | -37.84% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1299.599% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -79814.701% |
| Qrons Inc. | 1.48 Million USD | -1372.614% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -98.483% |
| SYBLEU INC | 681.41 Thousand USD | -3117.285% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2610.579% |
| Rebus Holdings, Inc. | 5.24 Million USD | -318.218% |
| Regen BioPharma, Inc. | 5.45 Million USD | -301.696% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -259.281% |
| Affymax, Inc. | 8.87 Million USD | -147.131% |
| Mobile Lads Corp. | 1.31 Million USD | -1569.056% |
| International Stem Cell Corporation | 5.27 Million USD | -315.444% |
| CytoDyn Inc. | 127.89 Million USD | 82.858% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -3403.146% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -374.819% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 46.524% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 1.536% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -982.41% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -300.201% |
| Neutra Corp. | 973.52 Thousand USD | -2151.91% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 24.443% |
| PureTech Health plc | 125.58 Million USD | 82.543% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -483.505% |
| IXICO plc | 1.9 Million USD | -1053.665% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -6.79% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 78.782% |
| CSL Limited | 18.62 Billion USD | 99.882% |
| Cellectis S.A. | 249.36 Million USD | 91.209% |